David A. Lane

18.2k total citations · 2 hit papers
340 papers, 13.9k citations indexed

About

David A. Lane is a scholar working on Hematology, Pulmonary and Respiratory Medicine and Genetics. According to data from OpenAlex, David A. Lane has authored 340 papers receiving a total of 13.9k indexed citations (citations by other indexed papers that have themselves been cited), including 186 papers in Hematology, 54 papers in Pulmonary and Respiratory Medicine and 47 papers in Genetics. Recurrent topics in David A. Lane's work include Blood Coagulation and Thrombosis Mechanisms (140 papers), Platelet Disorders and Treatments (56 papers) and Blood properties and coagulation (51 papers). David A. Lane is often cited by papers focused on Blood Coagulation and Thrombosis Mechanisms (140 papers), Platelet Disorders and Treatments (56 papers) and Blood properties and coagulation (51 papers). David A. Lane collaborates with scholars based in United Kingdom, United States and Italy. David A. Lane's co-authors include Ed Harlow, James T. B. Crawley, Ulf Lindahl, Helen Philippou, Peter J. Grant, David A. Freedman, H. Ireland, Rachel E. Simmonds, A. Flynn and Frits R. Rosendaal and has published in prestigious journals such as Proceedings of the National Academy of Sciences, The Lancet and Nucleic Acids Research.

In The Last Decade

David A. Lane

330 papers receiving 13.3k citations

Hit Papers

Using Antibodies: A Laboratory Manual 1989 2026 2001 2013 1998 1989 250 500 750
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Using Antibodies: A Laboratory Manual
    1998 886 citations David A. Lane et al. profile →
  2. Heparin : chemical and biological properties, clinical applications
    1989 429 citations David A. Lane, Ulf Lindahl profile →

Peers

David A. Lane
Comparison fields: 5 of 211
  • Hematology 7.3k
  • Internal Medicine 2.5k
  • Molecular Biology 2.4k
  • Cardiology and Cardiovascular Medicine 2.3k
  • Genetics 2.0k
Replace Robert Rosenberg with:
Robert Rosenberg United States
Stephen M. Schwartz United States
Donna Neuberg United States
Pascal J. Goldschmidt‐Clermont United States
Michael E. Weinblatt United States
Ching‐Hon Pui United States
Giovanni Scambia Italy
Anna E. Barón United States
Michael S. Pepper South Africa
Emil J. Freireich United States
Robert Rosenberg United States View profile →
Citations per field, relative to David A. Lane
David A. Lane · 1×
Citations per year, relative to David A. Lane
David A. Lane · 1×

Countries citing papers authored by David A. Lane

Since Specialization
Citations

This map shows the geographic impact of David A. Lane's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David A. Lane with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David A. Lane more than expected).

Fields of papers citing papers by David A. Lane

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David A. Lane. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David A. Lane. The network helps show where David A. Lane may publish in the future.

Co-authorship network of co-authors of David A. Lane

This figure shows the co-authorship network connecting the top 25 collaborators of David A. Lane. A scholar is included among the top collaborators of David A. Lane based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David A. Lane. David A. Lane is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
# Work Indexed citations
1
Laminin G1 residues of protein S mediate its TFPI cofactor function and are competitively regulated by C4BP
2021 ·Blood Advances ·(unknown), Magdalena Gierula, (unknown), David Jones, (unknown), (unknown), Salvatore Santamaria, James T. B. Crawley, David A. Lane, Josefin Ahnström
8
2
Objective measures of non-adherence in cardiometabolic diseases: a review focused on urine biochemical screening
2019 ·SHILAP Revista de lepidopterología ·David A. Lane, Prashanth Patel, Kamlesh Khunti, (unknown)
0
3
Enhanced activity of an ADAMTS‐13 variant (R568K/F592Y/R660K/Y661F/Y665F) against platelet agglutination in vitro and in a murine model of acute ischemic stroke
2018 ·Journal of Thrombosis and Haemostasis ·Kieron South, Frederik Denorme, Isabelle I. Salles‐Crawley, Simon F. De Meyer, David A. Lane
18
4
Plasma ADAMTS‐13 levels and the risk of myocardial infarction: an individual patient data meta‐analysis
2015 ·Journal of Thrombosis and Haemostasis ·Alberto Maino, Bob Siegerink, Luca A. Lotta, James T. B. Crawley, Saskia le Cessie, Frank W.G. Leebeek, David A. Lane, Gordon Lowe, Flora Peyvandi, Frits R. Rosendaal
49
5
Unraveling the scissile bond: how ADAMTS13 recognizes and cleaves von Willebrand factor
2011 ·Blood ·James T. B. Crawley, Rens de Groot, Yaozu Xiang, Brenda M. Luken, David A. Lane
214
6
COMPLEXITY AND THE ORGANIZATION OF ECONOMIC LIFE, Introduction
2010 ·History of economic ideas ·David A. Lane, Pietro Terna
1
7
Evidence that high von Willebrand factor and low ADAMTS‐13 levels independently increase the risk of a non‐fatal heart attack
2008 ·Journal of Thrombosis and Haemostasis ·James T. B. Crawley, David A. Lane, Mark Woodward, Ann Rumley, Gordon Lowe
80
8
Building on strength
2008 ·Journal of Thrombosis and Haemostasis ·M. Greaves, David A. Lane
16
9
Further characterization of ADAMTS‐13 inactivation by thrombin
2007 ·Journal of Thrombosis and Haemostasis ·Jonathan Lam, (unknown), Sara Zanardelli, David A. Lane, James T. B. Crawley
29
10
The central role of thrombin in hemostasis
2007 ·Journal of Thrombosis and Haemostasis ·James T. B. Crawley, Sara Zanardelli, (unknown), David A. Lane
272
11
Multifunctional Specificity of the Protein C/Activated Protein C Gla Domain
2006 ·Journal of Biological Chemistry ·Roger J. S. Preston, Éva Ajzner, Cristina Razzari, Stalo Karageorgi, (unknown), Björn Dahlbäck, David A. Lane
88
12
FACTOR-V LEIDEN AS AN INDEPENDENT RISK FACTOR FOR THROMBOSIS IN ANTITHROMBIN DEFICIENCY TYPE-II - HEPARIN-BINDING SITE
1995 ·UCL Discovery (University College London) ·(unknown), (unknown), Badrul Chowdhury, (unknown), J Conard, Ingrid Pabinger, David A. Lane
2
13
DERMATAN SULFATE IN HEMODIALYSIS
1992 ·UCL Discovery (University College London) ·David A. Lane, (unknown), (unknown), E. A. Curtis, Michael T. Nurmohamed, (unknown), (unknown), P Stevens, (unknown)
1
14
Antithrombin Budapest 3 An antithrombin variant with reduced heparin affinity resulting from the substitution L99F
1992 ·FEBS Letters ·R.J. Olds, David A. Lane, M Boisclair, G. Sas, S.C. Bock, S L Thein
47
15
ANTITHROMBIN FRANKFURT .1. ARGININE TO CYSTEINE SUBSTITUTION AT THE REACTIVE SITE AND FORMATION OF A VARIANT ANTITHROMBIN-ALBUMIN COVALENT COMPLEX
1991 ·UCL Discovery (University College London) ·H Ireland, David A. Lane, E.O.P. Thompson, R.J. Olds, SL Thein, (unknown), (unknown)
7
16
ANTITHROMBOTIC PROPERTIES OF DERMATAN SULFATE IN HEMODIALYSIS
1991 ·UCL Discovery (University College London) ·(unknown), H Ireland, David A. Lane, M Boisclair, (unknown), Curtis
1
17
Heparin : chemical and biological properties, clinical applications breakdown →
1989 ·David A. Lane, Ulf Lindahl
429
18
The effect of heparin on the inositol 1,4,5‐trisphosphate receptor in rat liver microsomes Dependence on sulphate content and chain length
1989 ·FEBS Letters ·Michael A. Tones, Martin D. Bootman, (unknown), David A. Lane, (unknown), Ulf Lindahl
61
19
Assessing methods for causality assessment of suspected adverse drug reactions
1989 ·Journal of Clinical Epidemiology ·Tom A. Hutchinson, David A. Lane
66
20
A Nonstochastic Interpretation of Reported Significance Levels
1983 ·Journal of Business and Economic Statistics ·David A. Freedman, David A. Lane
297

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Robert Rosenberg Breakdown of academic impact, for papers by Stephen M. Schwartz Breakdown of academic impact, for papers by Donna Neuberg Breakdown of academic impact, for papers by Pascal J. Goldschmidt‐Clermont Breakdown of academic impact, for papers by Michael E. Weinblatt Breakdown of academic impact, for papers by Ching‐Hon Pui Breakdown of academic impact, for papers by Giovanni Scambia Breakdown of academic impact, for papers by Anna E. Barón Breakdown of academic impact, for papers by Michael S. Pepper Breakdown of academic impact, for papers by Emil J. Freireich
Rankless by CCL
2026